Early detection, risk stratification, and drug target identification in pulmonary arterial hypertension with plasma proteomics
Early detection, risk stratification, and drug target identification in pulmonary arterial hypertension with plasma proteomics
Pulmonary arterial hypertension is a rare condition that is clinically heterogenous and often diagnosed late in disease progression. Plasma proteomics offers the potential to diagnose earlier, risk-stratify patients, and identify new drug targets.
Learning Objectives
- Pulmonary arterial hypertension as a clinical condition
- Applying proteomics to risk stratification
- Combining proteomics with genome-wide association studies to identify protein quantitative trait loci associated with the condition
Christopher Rhodes, MA, Cantab, PhD
Senior British Heart Foundation Science Fellow
Senior Lecturer
Imperial College London
Martin R. Wilkins
Professor of Clinical Pharmacology
Vice Dean of Research
Faculty of Medicine
Imperial College London
Early detection, risk stratification, and drug target identification in pulmonary arterial hypertension with plasma proteomics
A presentation by Christopher Rhodes, MA, Cantab, PhD, and Martin R. Wilkins
More webinars
WebinarEvaluation of precision and correlation for the latest proteomic platforms
The field of proteomics is rapidly advancing, enabling precise measurement of thousands of proteins, particularly those in higher abundance. This webcast will explore significant differences in precision within and across the latest large-scale proteomic platforms and their intercorrelations, based on blind duplicate split assays of the leading modified aptamer-based 11K and antibody proximity ligation-based 5K platforms. Each platform exhibits distinct strengths and limitations, requiring careful consideration prior to implementation in individual studies.
WebinarScaling Proteomics: Balancing Performance and Measuring Enough Proteins
As proteomics platforms have advanced, the number of proteins measured and sample throughput have dramatically increased. However, have sacrifices or trade-offs been necessary to make these gains? To find out, Stephen Williams will analyze how the performance of proteomics platforms has changed over time, comparing precision, sensitivity and specificity as throughput increases.
WebinarFrom discovery to clinical insights – the power of integrating proteomics and genomics data
The value of adding high-plex proteomics to existing genomics data and how proteogenomic approaches accelerate drug target discovery and repurposing. Watch this presentation given by Maik Pietzner, PhD, at ESHG 2024.